Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_4
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 4Post-market surveillance
3(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 43 (100.0%)

Trials by Status

not_yet_recruiting133%
recruiting133%
active_not_recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingphase_4

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

NCT06716424
recruitingphase_4

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

NCT06671587
not_yet_recruitingphase_4

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

NCT07307235

Clinical Trials (3)

Showing 3 of 3 trials
NCT06716424Phase 4

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

Active Not Recruiting
NCT06671587Phase 4

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

Recruiting
NCT07307235Phase 4

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3